Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists (Q37809456)

23 August 2017

title

Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists (English)

1 reference

23 August 2017

7

1 reference

23 August 2017

14

1 reference

23 August 2017

9

Jocelyne Jacquemier

0 references

Sunil R. Lakhani

Sunil R Lakhani

10

0 references

Emad A. Rakha

Emad A Rakha

12

0 references

Ian Ellis

Ian O Ellis

18

0 references

Jorge Reis-Filho

19

Jorge S Reis-Filho

1 reference

23 August 2017

17

Britta Weigelt

1 reference

23 August 2017

1

Sunil Badve

1 reference

23 August 2017

2

David J Dabbs

1 reference

23 August 2017

13

Andrea L Richardson

1 reference

23 August 2017

3

Stuart J Schnitt

1 reference

23 August 2017

4

Frederick L Baehner

1 reference

23 August 2017

Thomas Decker

5

1 reference

23 August 2017

Vincenzo Eusebi

6

1 reference

23 August 2017

Shu Ichihara

8

1 reference

23 August 2017

José Palacios

11

1 reference

23 August 2017

Puay-Hoon Tan

15

1 reference

23 August 2017

Gary M Tse

16

1 reference

23 August 2017

publication date

12 November 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

24

1 reference

23 August 2017

issue

2

1 reference

23 August 2017

page(s)

157-167

1 reference

Breast cancer special types: why bother?

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

The role of molecular analysis in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Refinement of breast cancer classification by molecular characterization of histological special types

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Histological and molecular types of breast cancer: is there a unifying taxonomy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

The molecular portraits of breast tumors are conserved across microarray platforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Basal-like breast cancer: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Supervised risk predictor of breast cancer based on intrinsic subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Molecular classification of breast cancer: limitations and potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Do 'basal-like' breast cancers really exist?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Impact of basal-like breast carcinoma determination for a more specific therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Patho-biological aspects of basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Basal-like breast carcinomas: clinical outcome and response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Molecular classification and molecular forecasting of breast cancer: ready for clinical application?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Breast cancer subtypes and the risk of local and regional relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

BRCA1 dysfunction in sporadic basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Typical medullary breast carcinomas have a basal/myoepithelial phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Metaplastic breast carcinomas are basal-like tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Nestin is expressed in basal-like and triple negative breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

CD109, a new marker for myoepithelial cells of mammary, salivary, and lacrimal glands and prostate basal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

CD109 expression in basal-like breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Are triple-negative and basal-like breast cancer synonymous?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Is acinic cell carcinoma a variant of secretory carcinoma? A FISH study using ETV6'split apart' probes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Triple-negative breast cancer: clinical features and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Prognostic markers in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Use of immunohistochemical markers can refine prognosis in triple negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Triple-negative breast cancer: risk factors to potential targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Are triple-negative tumours and basal-like breast cancer synonymous?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

How basal are triple-negative breast cancers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Breast cancer molecular profiling with single sample predictors: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Insight into microRNA regulation by analyzing the characteristics of their targets in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Identification of molecular apocrine breast tumours by microarray analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Hallmarks of 'BRCAness' in sporadic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Basal-like breast cancer and the BRCA1 phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Distinct Genetic and Epigenetic Changes in Medullary Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

BRCA1 transcriptionally regulates genes involved in breast tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Molecular alterations in columnar cell lesions of the breast.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Immunohistochemical categorisation of ductal carcinoma in situ of the breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Classification of ductal carcinoma in situ by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Molecular evidence for progression of microglandular adenosis (MGA) to invasive carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Microglandular adenosis or microglandular adenoma? A molecular genetic analysis of a case associated with atypia and invasive carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Expression of luminal and basal cytokeratins in human breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Concordance among gene-expression-based predictors for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Triple-negative/basal-like breast cancer: review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Subtypes of breast cancer show preferential site of relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Adenoid cystic carcinomas of the breast and salivary glands (or 'The strange case of Dr Jekyll and Mr Hyde' of exocrine gland carcinomas).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Platinum-based chemotherapy in triple-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

CT-X antigen expression in human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Targeting the DNA repair defect of BRCA tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Tumor size and survival in breast cancer--a reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Does tumor size trump biology?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

CK5 is more sensitive than CK5/6 in identifying the "basal-like" phenotype of breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

RNA-Seq: a revolutionary tool for transcriptomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

The beginning of the end for microarrays?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

EGFR amplification and lack of activating mutations in metaplastic breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

The death of microarrays?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

Potential chemotherapy options in the triple negative subtype of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

7 January 2021

Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

7 January 2021

Metastatic behavior of breast cancer subtypes

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

7 January 2021

KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

7 January 2021

Triple negative tumours: a critical review

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

7 January 2021

Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

7 January 2021

Microglandular adenosis with transition into adenoid cystic carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

7 January 2021

Carcinoma Arising in Microglandular Adenosis: An Immunohistochemical Analysis of 20 Intraepithelial and Invasive Neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

7 January 2021

Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.200

7 January 2021

10.1038/MODPATHOL.2010.200

Identifiers

DOI

1 reference

release_uaaqf5xqnvfl3lv2hbmhqkuezq

23 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/uaaqf5xqnvfl3lv2hbmhqkuezq

24 November 2022

mapped directly with Wikidata item

1 reference